Ingenix Secures €13M Seed Extension Led by Sofinnova to Advance Modality Fusion Architecture for Drug Discovery

On June 3, 2026, IngeniX announced the completion of a €13 million extended seed financing round, led by Sofinnova Partners, with participation from InnoVex Venture Capital and OTB Ventures.

Inginix is an artificial intelligence and biology company whose biological reasoning engine, built on a multimodal fusion architecture, integrates state-of-the-art models across modalities and biological scales to perform direct inference. In oncology collaborations, the engine has accomplished in minutes what partner companies had achieved over several years with millions of euros in research investment.

In a collaborative effort, the engine prioritized dual-payload antibody-drug conjugate (ADC) candidates for an oncology biotechnology company, proposing 15 candidate combinations. Among these, five were based on public hypotheses, two were supported by literature, three were validated through internal company experiments, five represented novel hypotheses, and three were flagged as actionable implementation plans. The engine performed reasoning based on underlying biological principles rather than pattern matching.

The funds will be used to scale up the research and development of the biological reasoning engine, expand collaborations with pharmaceutical and biotechnology partners through a high-quality access program. The application website is ingenix.ai/qap.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making. For accurate information, please refer to the actual announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express